Trial Profile
A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginesatide (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Pharmacodynamics
- Sponsors Affymax
- 23 May 2014 New trial record